Bilal Kaaki, MD
Urogynecology and Reconstructive Pelvic Surgery · Riverside, CANPI 1063464089
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $261,326 of the $301,309 with a category attached, or 86.7%. Valencia Technologies Corporation accounts for 91.8% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2023 at $176,497 and has fallen 71.2% since, to $50,746 in 2025. Among urogynecology and reconstructive pelvic surgery clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 148 payments — averaging $2035.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Valencia Technologies Corporation$276K
- Boston Scientific$17K
- Intuitive Surgical$4K
- Coloplast$1K
- C. R. Bard, Inc. & Subsidiaries$597
- Axonics, Inc.$397
- plus $2K from 13 others
Across 4 payments — averaging $32,431 each. An ownership or investment interest held by the physician or an immediate family member.
- Valencia Technologies Corporation$130K
What the payments were for
- Consulting fees$261,32687%
- Speaking & faculty fees$14,1125%
- Travel & lodging$17,5466%
- Food & beverage$4,3251%
- Education$4,0001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Valencia Technologies Corporation | 64 | $276,474 |
| Boston Scientific | 24 | $16,804 |
| Intuitive Surgical | 1 | $4,000 |
| Coloplast | 8 | $1,443 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $597 |
| Axonics, Inc. | 16 | $397 |
| BD | 1 | $265 |
| Caldera Medical, Inc | 4 | $257 |
| Caris MPI, Inc. | 2 | $238 |
| Medtronic(2 entities) | 5 | $197 |
| Astellas Pharma US Inc | 6 | $169 |
| Steris Corporation | 1 | $168 |
| Sumitomo Pharma America, Inc. | 6 | $114 |
| Smith+Nephew | 2 | $63 |
| Momentis Surgical Inc. | 1 | $51 |
| Minerva Surgical, Inc | 1 | $22 |
| Applied Medical Resources Corporation | 2 | $18 |
| AbbVie | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- eCoin Device Kit$275,690
- Solyx SIS System$14,656
- Da Vinci Surgical System$4,000
- ALTIS$1,114
- MI CANCER SEEK$238
- Desara$228
- TRUFREEZE$168
- Bulkamid$114
- Axonics r-SNM System$114
How this compares
$301,309 in reported general payments places this provider in the 95th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
See all urogynecology and reconstructive pelvic surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 254 | $122,047 |
| Mirabegron ErMirabegron | 17 | $5,799 |
| Estradiol | 60 | $3,427 |
| Oxybutynin Chloride ErOxybutynin Chloride | 134 | $1,432 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 65 | $932 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 141 | $393 |
| Ondansetron Hcl | 200 | $249 |
| Solifenacin Succinate | 13 | $195 |
| Clobetasol Propionate | 18 | $183 |
| Meloxicam | 184 | $172 |
| Ibuprofen | 24 | $105 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 21 | $27 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $169 | $122,047254 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
Other urogynecology and reconstructive pelvic surgery in Riverside
- Mikio NihiraRiverside$13K
- Andrew BrillSan Francisco$345K
- Savitha KrishnanMountain View$243K
- Peter CastilloLos Gatos$95K
- Bruce Kahnla Jolla$79K
- Jennifer GruenenfelderOrange$76K
- Traci ItoSan Francisco$68K
- Tanaz FerzandiLos Angeles$60K
- Sadikah BehbehaniCosta Mesa$53K
- Christopher TarnayLos Angeles$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.